Abstract

Elevated oxidative stress in cancer cells contributes to hyperactive proliferation and enhanced survival, which can be exploited using agents that increase reactive oxygen species (ROS) beyond a threshold level. Here we show that melanoma cells exhibit an oxidative stress phenotype compared with normal melanocytes, as evidenced by increased total cellular ROS, KEAP1/NRF2 pathway activity, protein damage, and elevated oxidized glutathione. Our overall objective was to test whether augmenting this high oxidative stress level in melanoma cells would inhibit their dependence on oncogenic PI3K/AKT/mTOR-mediated survival. We report that NexrutineR augmented the constitutively elevated oxidative stress markers in melanoma cells, which was abrogated by N-acetyl cysteine (NAC) pre-treatment. NexrutineR disrupted growth homeostasis by inhibiting proliferation, survival, and colony formation in melanoma cells without affecting melanocyte cell viability. Increased oxidative stress in melanoma cells inhibited PI3K/AKT/mTOR pathway through disruption of mTORC1 formation and phosphorylation of downstream targets p70S6K, 4EBP1 and rpS6. NAC pre-treatment reversed inhibition of mTORC1 targets, demonstrating a ROS-dependent mechanism. Overall, our results illustrate the importance of disruption of the intrinsically high oxidative stress in melanoma cells to selectively inhibit their survival mediated by PI3K/AKT/mTOR.

Highlights

  • Metastatic melanoma is associated with poor prognosis, disease aggressiveness and resistance to chemotherapeutic strategies [1]

  • We report that NexrutineR augmented the constitutively elevated oxidative stress markers in melanoma cells, which was abrogated by N-acetyl cysteine (NAC) pre-treatment

  • Peroxy Orange-1 (PO-1), which detects H2O2-specific reactive oxygen species (ROS), was higher in melanoma cells compared with human epidermal neonatal melanocytes (HEMn) suggesting that part of the total ROS generated is from H2O2 (Figure 1B)

Read more

Summary

Introduction

Metastatic melanoma is associated with poor prognosis, disease aggressiveness and resistance to chemotherapeutic strategies [1]. Lin and colleagues used a model based on incidence, recurrence, death from all causes, SEER www.impactjournals.com/oncotarget data, US census and reports in the published literature to predict the total number of melanoma and advanced melanomas in the US According to this model, total and advanced melanoma cases will increase by 24.4 and 21% respectively between 2010 and 2015 [3]. Overall cancer-related mortality is reportedly decreasing, this trend does not appear to apply to malignant melanoma. This may in part be due to the lack of a full understanding of the mechanisms involved in melanomagenesis that hinders development of effective therapeutic modalities

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call